Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial.

Vilca I, Munitis PG, Pistorio A, Ravelli A, Buoncompagni A, Bica B, Campos L, Häfner R, Hofer M, Ozen S, Huemer C, Bae SC, Sztajnbok F, Arguedas O, Foeldvari I, Huppertz HI, Gamir ML, Magnusson B, Dressler F, Uziel Y, van Rossum MA, Hollingworth P, Cawkwell G, Martini A, Ruperto N; Pediatric Rheumatology International Trials Organisation (PRINTO).

Ann Rheum Dis. 2010 Aug;69(8):1479-83. doi: 10.1136/ard.2009.120840. Epub 2010 Jun 4.

PMID:
20525842
2.

Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis.

Céspedes-Cruz A, Gutiérrez-Suárez R, Pistorio A, Ravelli A, Loy A, Murray KJ, Gerloni V, Wulffraat N, Oliveira S, Walsh J, Penades IC, Alpigiani MG, Lahdenne P, Saad-Magalhães C, Cortis E, Lepore L, Kimura Y, Wouters C, Martini A, Ruperto N; Pediatric Rheumatology International Trials Organization (PRINTO).

Ann Rheum Dis. 2008 Mar;67(3):309-14. Epub 2007 Sep 17.

PMID:
17875547
3.

A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.

Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, Dolezalova P, Alessio M, Burgos-Vargas R, Corona F, Vesely R, Foster H, Davidson J, Zulian F, Asplin L, Baildam E, Consuegra JG, Ozdogan H, Saurenmann R, Joos R, Pistorio A, Woo P, Martini A; Pediatric Rheumatology International Trials Organization.

Arthritis Rheum. 2004 Jul;50(7):2191-201.

4.

The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis.

Bartoli M, Tarò M, Magni-Manzoni S, Pistorio A, Traverso F, Viola S, Magnani A, Gasparini C, Martini A, Ravelli A.

Ann Rheum Dis. 2008 Mar;67(3):370-4. Epub 2007 Jul 27.

PMID:
17660217
5.
6.

[Methotrexate treatment in refractory juvenile rheumatoid arthritis].

Brik R.

Harefuah. 1998 Dec 1;135(11):509-11, 567. Hebrew.

PMID:
10911466
8.

Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.

Tynjälä P, Vähäsalo P, Tarkiainen M, Kröger L, Aalto K, Malin M, Putto-Laurila A, Honkanen V, Lahdenne P.

Ann Rheum Dis. 2011 Sep;70(9):1605-12. doi: 10.1136/ard.2010.143347. Epub 2011 May 28.

PMID:
21623000
9.

Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis.

Albers HM, Wessels JA, van der Straaten RJ, Brinkman DM, Suijlekom-Smit LW, Kamphuis SS, Girschick HJ, Wouters C, Schilham MW, le Cessie S, Huizinga TW, Ten Cate R, Guchelaar HJ.

Arthritis Rheum. 2009 Jan 15;61(1):46-51. doi: 10.1002/art.24087.

10.

Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis.

Papadopoulou C, Kostik M, Böhm M, Nieto-Gonzalez JC, Gonzalez-Fernandez MI, Pistorio A, Martini A, Ravelli A.

J Pediatr. 2013 Sep;163(3):879-84. doi: 10.1016/j.jpeds.2013.03.047. Epub 2013 May 9.

PMID:
23664559
13.

Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.

Silverman E, Spiegel L, Hawkins D, Petty R, Goldsmith D, Schanberg L, Duffy C, Howard P, Strand V.

Arthritis Rheum. 2005 Feb;52(2):554-62.

14.

Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. II. Early predictors of outcome.

Ruperto N, Ravelli A, Levinson JE, Shear ES, Murray K, Link Tague B, Martini A, Glass DN, Giannini EH.

J Rheumatol. 1997 May;24(5):952-8.

PMID:
9150088
15.

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.

Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, Beutler A, Keenan G, Clark J, Visvanathan S, Fasanmade A, Raychaudhuri A, Mendelsohn A, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group.

Arthritis Rheum. 2007 Sep;56(9):3096-106.

16.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

PMID:
16705046
18.

Methotrexate for treating juvenile idiopathic arthritis.

Takken T, Van der Net J, Helders PJ.

Cochrane Database Syst Rev. 2001;(3):CD003129. Review. Update in: Cochrane Database Syst Rev. 2001;(4):CD003129.

PMID:
11687037
19.

Methotrexate for treating juvenile idiopathic arthritis.

Takken T, Van Der Net J, Helders PJ.

Cochrane Database Syst Rev. 2001;(4):CD003129. Review.

PMID:
11687174
20.

Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease.

Ravelli A, Felici E, Magni-Manzoni S, Pistorio A, Novarini C, Bozzola E, Viola S, Martini A.

Arthritis Rheum. 2005 Mar;52(3):826-32.

Supplemental Content

Support Center